Immersion Corporation (IMMR) NasdaqGS - NasdaqGS Real Time Price. Currency in USD 8.22-0.24 (-2.84%) At close: July 6 4:00PM EDT $9.00 +0.78 (9.49%)<--------------- Pre-Market: 08:20AM EDT
Bond Yields are getting too low and people are going to freak out. Top-tier investors Along with Navistar, TuSimple's strategic investors include Volkswagen's (OTC:VWAGY) heavy-truck business Traton, which is in the process of acquiring Navistar; UPS; Union Pacific; Goodyear; and U.S. Xpress. Graphics processing unit (GPU) specialist NVIDIA was one of TuSimple's early investors. In 2017, it participated in a more than $20 million funding round of TuSimple, which incorporates some of NVIDIA's technologies in its self-driving tech, as I wrote at the time. Its TuSimple investment was NVIDIA's first investment in the self-driving truck space. Cathie Wood began buying shares of TuSimple on the day of the company's IPO, and ramped up her buying after the company reported its Q1 results in May. The stock is Ark Innovation's 28th largest holding, accounting for 1.22% of its value, as of June 14. And it's the 22nd largest holding in the Ark Autonomous Technology & Robotics ETF, accounting for 1.56% of its value as of the same date. Together, Ark's two ETFs own about 2.2% of TuSimple's shares.
It's down 8.5% on the day. I wonder if ol' Christopher realizes that 24,500,000 shares of Affirm go post-lockup Monday, 7/12. Should have put this in Granny's shorts yesterday at $70...
Lots of Biohaven chatter BHVN. Cramer extolled the migraine medicine this morning. I missed it but my wife saw and reported. GBA has never owned BCOV, BFLY or CRVS.
Jefferies analyst Owen Bennett assumes federal legalization kicking in as of 2026 Jefferies analyst Owen Bennett initiated coverage of seven U.S. cannabis stocks, including five he sees having the potential to about double from current levels, driven by industry growth, further consolidation, and institutional led re-rating. The analyst believes preferred names Cresco (CRLBF), Curaleaf (CURLF) and Green Thumb (GTBIF) are better aligned for success in a likely longer-term industry structure, citing their exposure to key states, interstate positioning and CBD/international optionality. GENERATIONAL WEALTH OPPORTUNITY: Jefferies analyst Owen Bennett started coverage of seven U.S. cannabis stocks with Buy ratings, setting price targets of C$17 for TerrAscend (TRSSF), C$80 for Ayr Wellness (AYRWF), C$19 for Columbia Care (CCHWF), C$36 for Cresco Labs, C$62 for Trulieve Cannabis (TCNNF), C$70 for Green Thumb Industries, and C$32 for Curaleaf. The analyst argued that this is a "generational wealth opportunity" with potential average expected 12-month gains across the coverage to be over 100%. This will be driven by "exceptional" industry growth, further consolidation in a fragmented industry, and institutional led sector re-rating, Bennett contended. He estimates the U.S. cannabis industry retail sales in 2020 were $17.2B, a 40% increase versus 2019. By 2025, Bennett sees industry sales reaching $36B and $64B by 2030, with an assumption of federal legalization kicking in as of 2026. The analyst also sees further consolidation ahead, supported by M&A. With an estimated 27,000 plant touching businesses currently in operation, the space is primed for further consolidation, he added, noting that M&A has been a key tool, and he expects this to persist — with added urgency to scale ahead of near-term reform leading to new competitive entrants and the state structure making organic growth more difficult. Additionally, Bennett believes that institutional driven sector re-rating will be material. Despite compelling fundamentals, institutional participation minimal at just 4%, as most institutions cannot own currently due to federal illegality and a lack of capital market protections, the analyst noted. He expects, however, protection to be provided very soon - next 12 months - via either Schumer Bill/SAFE Banking. Overall, the analyst believes preferred names Cresco, Curaleaf, and Green Thumb are better aligned for success in a likely longer-term industry structure, namely exposure to key states, branding/wholesale, robust balance sheet, interstate positioning and CBD/international optionality.
Watch this and try to grab at low of day) Biohaven emerging as 'major migraine player,' says Piper Sandler 09:32 BHVN Piper Sandler analyst Christopher Raymond says Biohaven Pharmaceutical/s preliminary Q2 Nurtec revenue of $93M dwarfed the consensus of $54.7M and his estimate of $61.8M. Management specifically cited strong early uptake trends in the prevention setting during the final weeks of the quarter, Raymond tells investors in a research note. Along with the Phase 3 data for intranasal zavegepant in acute migraine coming in the second half of 2021, the analyst thinks Biohaven is "emerging as a major migraine player." He conitinues to like the setup for shares and keeps an Overweight rating on the name.
This would be the spot to initiate gummy. I just don't have much faith in the market. And these guys have surprised on the upside before. Immersion Corporation (IMMR) NasdaqGS - NasdaqGS Real Time Price. Currency in USD 8.43+0.21 (+2.55%)<----------------- As of 11:31AM EDT. Market open.
Well you sure have talked about that stupid Butterfly quite a bit. It's hard to figure out what exactly is in the GBA portfolio. Best I ascertain at this point is you preface them with "added to the phantasma". Aaaanyway Stoney.... Speaking of canines.... WOOF is also on my list of upcoming lock-ups best that I can tell. 48,000,000 shares next week sometime. ****For the readers.... VZ's ez tip for lock-up expiration's.... The lock-up deal on most IPO's is almost always 180 days, so the thing to use is a daily chart, set it to 120 days, and see which stocks ipo'd near the first date on the chart. 180 calendar days equals about 125 trading days, give or take one or two depending on holidays.